Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23204878 | 0.89 | CHRM5 (0.39) | CHRM5ADRA2CSIGMAR1ACHEGBA1 | |
| SCHEMBL13884111 | 0.89 | GBA1 (0.32) | CHRM5ADRA2CACHEGBA1CACNA2D1 | |
| SCHEMBL13884112 | 0.84 | GNAO1 (0.35) | ACHEGBA1 | |
| SCHEMBL22907459 | 0.84 | GBA1 (0.36) | GBA1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL22907052 | 0.83 | GBA1 (0.41) | CHRM5ADRA2CSIGMAR1ACHEGBA1 | |
| SCHEMBL26157173 | 0.82 | GBA1 (0.34) | CHRM5ADRA2CACHEGBA1CACNA2D1 | |
| SCHEMBL23205744 | 0.82 | ACHE (0.35) | CHRM5ADRA2CACHEGBA1CACNA2D1 | |
| SCHEMBL26157174 | 0.82 | GBA1 (0.34) | CHRM5ADRA2CACHEGBA1CACNA2D1 | |
| SCHEMBL23205510 | 0.82 | ACHE (0.35) | CHRM5ADRA2CACHEGBA1CACNA2D1 | |
| SCHEMBL24414411 | 0.79 | ACHE (0.40) | CHRM5ADRA2CSIGMAR1ACHEGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
| EP-1646620-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | CHRM5 184/4885ADRA2C 173/4885SIGMAR1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.